Paeds Vivas · nephrology-urology-fluids-and-electrolytes
Oedema and nephrotic syndrome — branching viva
Branching viva from the puffy toddler at first presentation, through the KDIGO 2021 definition and the initial prednisolone regimen, the four-week response classification that separates steroid-sensitive from steroid-resistant disease, the move to steroid-sparing therapy in the frequently-relapsing child, to the unwell nephrotic child with abdominal pain who demands recognition of peritonitis and hypovolaemia.
On this page & tools
Target exams
Stem 1 — Three-year-old with new oedema and heavy proteinuria (5 minutes)
A three-year-old boy has four days of morning periorbital puffiness and ankle swelling. A first morning urine protein-to-creatinine ratio is 290 mg/mmol, his serum albumin is 20 g/L, his blood pressure is normal, his complement is normal, and there is no haematuria. [1]
Branch A (examiner): State the KDIGO 2021 diagnostic criteria, and explain why the first morning sample is essential rather than a random daytime dipstick. (2 marks) [1] [10]
Branch B (examiner): Outline the initial prednisolone regimen in full, including the daily dose, the maximum, the conversion to alternate-day dosing, and the total course duration. Why is the course kept within twelve weeks? (2 marks) [1] [3]
Branch C (examiner): What will you teach the family to do at home, and what are the three danger signs that should prompt them to seek urgent review? (1 mark) [11]
Stem 2 — Seven-year-old not cleared after four weeks of steroids (5 minutes)
A seven-year-old boy started daily prednisolone 60 mg/m2/day four weeks ago for a first episode of nephrotic syndrome. His home dipsticks have shown persistent 3+ protein throughout, and he remains oedematous. His blood pressure is at the 95th percentile and his complement is normal. [5]
Branch A (examiner): What is the correct diagnostic label at this point, and how does it change the management pathway compared with the steroid-sensitive child? (2 marks) [1] [5]
Branch B (examiner): Outline the investigations you would now request, including the role of renal biopsy and genetic testing, and the first-line pharmacological agent class you would introduce. (2 marks) [5] [6]
Branch C (examiner): What is the prognostic significance of steroid resistance for this child's long-term kidney function, and how does the finding of a pathogenic genetic variant alter the counselling about treatment and transplant? (1 mark) [5] [6]
Stem 3 — Five-year-old with frequently-relapsing disease, abdominal pain and fever (5 minutes)
A five-year-old girl with frequently-relapsing steroid-sensitive nephrotic syndrome (four relapses in the last year) presents with a new relapse, now complicated by abdominal pain, fever of 38.8 degrees Celsius and tachycardia. Her capillary refill is 4 seconds and her serum albumin is 14 g/L. [11]
Branch A (examiner): What complication must you assume is present, what is the immediate investigation and empirical treatment, and why is she vulnerable to it? (2 marks) [11]
Branch B (examiner): She is also intravascularly depleted despite her oedema. State the resuscitation fluid, the dose and the accompanying drug, and explain why diuretics alone would be dangerous. (2 marks) [7]
Branch C (examiner): Once she is stabilised, what steroid-sparing options are now indicated for her frequently-relapsing course, and what is the evidence-based role of rituximab? (1 mark) [1] [4]
References
- [1]Rovin BH; Adler SG; Barratt J; et al Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int, 2021.PMID 34556300
- [2]Rovin BH; Caster DJ; Cattran DC; et al Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int, 2019.PMID 30665569
- [3]Teeninga N; Kist-van Holthe JE; van Rijswijk N; et al Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome. J Am Soc Nephrol, 2013.PMID 23274956
- [4]Iijima K; Sako M; Nozu K; et al Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet, 2014.PMID 24965823
- [5]Trautmann A; Vivarelli M; Samuel S; et al IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol, 2020.PMID 32382828
- [6]Tullus K; Webb H; Bagga A; et al Management of steroid-resistant nephrotic syndrome in children and adolescents. Lancet Child Adolesc Health, 2018.PMID 30342869
- [7]Rheault MN; Zhang L; Selewski DT; et al AKI in Children Hospitalized with Nephrotic Syndrome. Clin J Am Soc Nephrol, 2015.PMID 26450933
- [8]Kerlin BA; Haworth K; Smoyer WE; et al Venous thromboembolism in pediatric nephrotic syndrome. Pediatr Nephrol, 2014.PMID 23812352
- [9]Boyer O; Schaefer F; Haffner D; et al Management of congenital nephrotic syndrome: consensus recommendations of the ERKNet-ESPN Working Group. Nat Rev Nephrol, 2021.PMID 33514942
- [10]Bagga A; Mantan M Nephrotic syndrome in children. Indian J Med Res, 2005.PMID 16106086
- [11]Gipson DS; Massengill SF; Yao L; et al Management of childhood onset nephrotic syndrome. Pediatrics, 2009.PMID 19651590
- [12]Zhu H; Qi J; Schoepf J; et al Prevalence and Associated Risk Factors of Pulmonary Embolism in Children and Young Adults With Nephrotic Syndrome: A Chinese Large Cohort Study. J Thorac Imaging, 2021.PMID 34269751